ClinOne, a provider of technologies for clinical trials, is set to launch a direct-to-patient recruitment platform in the first quarter of next year.
The new platform, known as ClinTrialConnect, will provide recruitment in the first quarter of the year in the US, expanding to other regions the subsequent quarter. It will enable patients to navigate clinical trial options from their home or place of work.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The new technology will automatically integrate with disease associations and social media, including Google and Facebook.
ClinTrialConnect technology will include screening questions for patients, thereby, mitigating unqualified patients being admitted into trials.
According to the company, the series of screening questions for patients and their caretakers will be designed to better understand their disease and identify which patients match a specific trial.
ClinOne CEO Rob Bohacs said: “In our initial launch phase of this technology, we would like to have sponsors pilot our technology at no cost through 2020, measure success, and provide valuable feedback to our organization.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“This feedback will ultimately benefit all sponsors as it will help us improve upon the app, should we see from the data that this is indicated.”
In May this year, ClinOne unveiled the new Bring Your Own Device (BYOD) electronic patient-reported outcome (ePRO) to ensure zero data loss at clinical trial sites.
The solution is anticipated to support site sponsors by reducing the cost over hardware-derived ePRO solutions and the need to allocate provisioned devices.
Based in Denver, Colorado, ClinOne is a provider of mobile and web applications that enhance patient, family, and site engagement.
